Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). WuXi XDC Cayman's share price for the quarter that ended in Jun. 2023 was HK$0. WuXi XDC Cayman's Shares Outstanding (EOP) for the quarter that ended in Jun. 2023 was 1,178 Mil. Therefore, WuXi XDC Cayman's market cap for the quarter that ended in Jun. 2023 was HK$0 Mil.
WuXi XDC Cayman's annual market cap
stayed the same
from Dec. 2021 (HK$0 Mil) to Dec. 2022 (HK$0 Mil) but then
increased
from Dec. 2022 (HK$0 Mil) to Dec. 2023 (HK$38,323 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. WuXi XDC Cayman's Enterprise Value for Today is HK$18,451 Mil.
WuXi XDC Cayman Market Cap Historical Data
The historical data trend for WuXi XDC Cayman's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of WuXi XDC Cayman's Market Cap
For the Diagnostics & Research subindustry, WuXi XDC Cayman's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman's Market Cap Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's Market Cap distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's Market Cap falls into.
WuXi XDC Cayman Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
WuXi XDC Cayman's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi XDC Cayman (HKSE:02268) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
WuXi XDC Cayman Market Cap Related Terms
Thank you for viewing the detailed overview of WuXi XDC Cayman's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
No. 11 Xinhui Ring Road, Xinwu, Jiangsu, Wuxi, CHN
Website
WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02268 has been successfully added to your